Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
Patent 5532278 Issued on July 2, 1996. Estimated Expiration Date: 
January 31, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
January 31, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 5236956 Transdermal administration of oxybutynin Patent #: 5411740 InventorsAssigneeApplicationNo. 381542 filed on 01/31/1995US Classes:514/617, R contains benzene ring424/449, Transdermal or percutaneous424/451, Capsules (e.g., of gelatin, of chocolate, etc.)424/464, Tablets, lozenges, or pills514/946PENETRANT OR ABSORBENT (ENHANCES PENETRATION INTO SUBJECT TREATED)ExaminersPrimary: Rollins, John W.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/165A61K 009/70 AbstractA method for treating urinary incontinence while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering a therapeutically effective amount of (S)-oxybutynin or a pharmaceutically acceptable salt thereof, substantially free of its R enantiomer. Pharmaceutical compositions comprising (S)-oxybutynin and an acceptable carrier are also disclosed.Other References
Field of SearchNitrogen, other than as nitro or nitroso, attached directly to the isoquinoline ring system by nonionic bondingR contains benzene ring PENETRANT OR ABSORBENT (ENHANCES PENETRATION INTO SUBJECT TREATED) Transdermal or percutaneous Capsules (e.g., of gelatin, of chocolate, etc.) Tablets, lozenges, or pills | |
